Treatment of basal cell carcinoma with vismodegib: future or present?
Sign Up to like & getrecommendations! Published in 2019 at "Acta Chirurgica Belgica"
DOI: 10.1080/00015458.2019.1658943
Abstract: Abstract Background Since the introduction of Vismodegib as treatment of recurrent locally advanced basal cell carcinoma (laBCC), clinicians are faced with new dilemmas: ‘Can Vismodegib replace complex reconstructions?’, ‘What is the role of neoadjuvant use… read more here.
Keywords: cell carcinoma; basal cell; vismodegib;
Amenorrhea secondary to vismodegib: An adverse event to consider especially in female patients with Gorlin‐Goltz syndrome
Sign Up to like & getrecommendations! Published in 2020 at "Dermatologic Therapy"
DOI: 10.1111/dth.13527
Abstract: Dear Editor, Vismodegib, a first-in-class inhibitor of the hedgehog signaling pathway, is indicated to treat metastatic or locally advanced basal cell carcinoma (BCC). Mutations in Patched 1 (PTCH1) and smoothened (SMO) proteins of the Hedgehog… read more here.
Keywords: amenorrhea secondary; goltz syndrome; vismodegib; gorlin goltz ... See more keywords
Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma – real world multicenter cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.18070
Abstract: Basal cell carcinoma (BCC) is the most frequent non‐melanoma skin cancer. The basis of treatment is surgical resection. The treatment of locally advanced and metastatic disease is currently based on sonidegb or vismodegib, small molecule… read more here.
Keywords: vismodegib; basal cell; cell carcinoma;
Abstract LB-136: Characterization of residual Basal Cell Carcinoma after vismodegib treatment
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-lb-136
Abstract: We have generated a mouse model of Superficial Basal Cell Carcinoma (BCC) to study the effect of the Smoothened inhibitor vismodegib in vivo. Despite the potency of vimodegib in blocking Hedgehog (Hh) signaling and efficacy… read more here.
Keywords: cell carcinoma; treatment; vismodegib; basal cell ... See more keywords
Vismodegib treatment in locally advanced basal cell carcinoma limited to the facial region: a single-center experience
Sign Up to like & getrecommendations! Published in 2025 at "BMC Cancer"
DOI: 10.1186/s12885-025-14914-2
Abstract: Basal cell carcinoma (BCC) is the most common non-melanoma skin cancer. Treatment typically begins with surgical intervention. However, in cases of locally advanced and metastatic BCC (laBCC and mBCC), Hedgehog signaling pathway inhibitors such as… read more here.
Keywords: treatment; basal cell; locally advanced; vismodegib ... See more keywords
Treatment of locally advanced or multiple basal cell carcinoma with vismodegib in real world setting.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e22065
Abstract: e22065Background: Evaluation of efficacy and safety of vismodegib (V) was done in a retrospective analysis of patients (pts) with locally advanced or multiple basal cell carcinoma (laBCC or multipl... read more here.
Keywords: advanced multiple; cell carcinoma; vismodegib; basal cell ... See more keywords
Structure-based discovery of potent USP28 inhibitors derived from Vismodegib.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of medicinal chemistry"
DOI: 10.2139/ssrn.4367388
Abstract: Ubiquitin-specific proteases (USPs) 28 is overexpressed in multiple types of cancers. The development of potent USP28 inhibitors is still in primitive stage. We previously reported our discovery of Vismodegib as a USP28 inhibitor by screening… read more here.
Keywords: vismodegib; usp28 inhibitors; structure based; potent usp28 ... See more keywords
Long-Term Success in the Management of an Extensive Medial Canthal Basal-Cell Carcinoma with Vismodegib
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Current Ophthalmology"
DOI: 10.4103/joco.joco_76_24
Abstract: Purpose: To present a case of an extensive basal-cell carcinoma (BCC) of the medial canthus that was successfully treated with vismodegib. The introduction of vismodegib and other Hedgehog pathway inhibitors into clinical practice has provided… read more here.
Keywords: basal cell; cell carcinoma; vismodegib;